A Dose Ascending Study of Gemcitabine Elaidate (CO-101) in Combination With Cisplatin
Status:
Terminated
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
The purpose of the first part of the study is to evaluate the safety, tolerability, and
pharmacokinetics of ascending doses of gemcitabine elaidate in combination with cisplatin
given to patients with advanced solid tumors, and to select a dose for further evaluation in
the second part of the study.
The purpose of the second part of the study is to determine the safety, tolerability, and
exploratory clinical activity of gemcitabine elaidate in combination with cisplatin given to
patients with Stage IIIb/IV non-small-cell lung cancer (NSCLC).